ArticleJTO clinical and research reports2026
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: EGFR tyrosine kinase inhibitors, including osimertinib, generally exhibit lower efficacy in patients with the L858R-mutant NSCLC compared with those with exon 19 deletion (del19). Ramucirumab (RAM) plus erlotinib (ERL), however, has demonstrated comparable efficacy in patients with either del19 or L858R mutations. Despite these findings, the real-world clinical efficacy of the RAM plus ERL combination therapy for the L858R-mutation NSCLC remains unclear, particularly in patients with central nervous system metastases. Methods: The authors performed a retrospective multicenter cohort study for 168 patients with L858R-mutant NSCLC treated with RAM plus ERL as a first-line treatment between November 2020 and August 2023. Results: The median time to treatment failure was 12.2 months (95% confidence interval [CI]: 9.5-15.5), and the median progression-free survival was 17.4 months (95% CI: 14.8-24.8). The median overall survival was 35.6 months (95% CI: 30.3-not calculable), resulting in 77.8% at a 2-year survival rate. The objective response rate was 75.0%, and the disease control rate was 88.7%. Among the cohort, 43 patients (26%) had central nervous system metastasis, with a median progression-free survival of 15.1 months (95% CI: 8.2-19.9). The most common adverse events were dermatitis acneiform (71%), paronychia (43%), and diarrhea (39%). Grade more than or equal to 3 adverse events occurred in 42% of patients. Conclusions: In real-world settings, RAM plus ERL demonstrated favorable efficacy in patients with L858R-mutant NSCLC and manageable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.